Parallax Volatility Advisers
SRPT icon

Parallax Volatility Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Parallax Volatility Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,800
Closed -$512K – 1810
2025
Q4 		$512K Hold
23,800
– – ﹤0.01% 1222
2025
Q3 		$459K Hold
23,800
– – ﹤0.01% 1259
2025
Q2 		$407K Hold
23,800
– – ﹤0.01% 1225
2025
Q1 		$1.52M Sell
23,800
-8,800
-27% -$926K ﹤0.01% 946
2024
Q4 		$3.96M Sell
32,600
-21,000
-39% -$2.57M 0.01% 916
2024
Q3 		$6.69M Sell
53,600
-121,300
-69% -$16.8M 0.01% 687
2024
Q2 		$27.6M Buy
174,900
+104,600
+149% +$13.4M 0.06% 230
2024
Q1 		$9.1M Buy
70,300
+41,700
+146% +$5.11M 0.02% 535
2023
Q4 		$2.76M Buy
28,600
+26,500
+1,262% +$2.54M 0.01% 1060
2023
Q3 		$255K Buy
2,100
+1,200
+133% +$136K ﹤0.01% 1760
2023
Q2 		$103K Sell
900
-103,000
-99% -$13.3M ﹤0.01% 1989
2023
Q1 		$14.3M Buy
103,900
+29,300
+39% +$3.8M 0.03% 460
2022
Q4 		$9.67M Buy
74,600
+37,700
+102% +$4.37M 0.02% 786
2022
Q3 		$4.08M Buy
36,900
+35,100
+1,950% +$3.54M 0.01% 1110
2022
Q2 		$135K Sell
1,800
-100
-5% -$7.36K ﹤0.01% 2291
2022
Q1 		$148K Sell
1,900
-40,200
-95% -$3.08M ﹤0.01% 2269
2021
Q4 		$3.79M Buy
42,100
+22,600
+116% +$1.93M ﹤0.01% 863
2021
Q3 		$1.8M Sell
19,500
-30,500
-61% -$2.35M ﹤0.01% 1155
2021
Q2 		$3.89M Buy
50,000
+34,000
+213% +$2.58M 0.01% 732
2021
Q1 		$1.19M Buy
16,000
+11,200
+233% +$1.03M ﹤0.01% 795
2020
Q4 		$816K Sell
4,800
-99,300
-95% -$14.7M ﹤0.01% 1508
2020
Q3 		$14.6M Buy
104,100
+28,600
+38% +$4.35M 0.01% 832
2020
Q2 		$12.1M Buy
75,500
+59,700
+378% +$8.12M 0.01% 700
2020
Q1 		$1.55M Buy
+15,800
New +$1.81M ﹤0.01% 1329
2019
Q4 		– Sell
-40,000
Closed -$3.01M – 2626
2019
Q3 		$3.01M Buy
+40,000
New +$4.72M ﹤0.01% 991
2019
Q1 		– Sell
-20,000
Closed -$2.18M – 3955
2018
Q4 		$2.18M Hold
20,000
– – ﹤0.01% 1028
2018
Q3 		$3.23M Sell
20,000
-28,500
-59% -$3.9M ﹤0.01% 873
2018
Q2 		$6.41M Buy
48,500
+28,500
+143% +$2.69M 0.01% 550
2018
Q1 		$1.48M Hold
20,000
– – ﹤0.01% 852
2017
Q4 		$1.11M Buy
20,000
+19,900
+19,900% +$1.05M ﹤0.01% 1149
2017
Q3 		$5K Sell
100
-88,600
-100% -$3.54M ﹤0.01% 1861
2017
Q2 		$2.99M Buy
+88,700
New +$2.89M 0.01% 713
2016
Q3 		– Sell
-100,000
Closed -$1.91M – 3867
2016
Q2 		$1.91M Buy
+100,000
New +$1.85M ﹤0.01% 946
2016
Q1 		– Sell
-20,000
Closed -$772K – 3606
2015
Q4 		$772K Hold
20,000
– – ﹤0.01% 1370
2015
Q3 		$642K Hold
20,000
– – ﹤0.01% 1443
2015
Q2 		$609K Buy
+20,000
New +$409K ﹤0.01% 1539

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's SRPT Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 85 shares — an estimated $1.83K sold.

Parallax Volatility Advisers first reported a position in SRPT in Q3 2016 and held it in 20 quarters. The position peaked at $4.45M in Q4 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Parallax Volatility Advisers reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 85 Sarepta Therapeutics shares in Q1 2026, an estimated $1.83K.
  • Parallax Volatility Advisers first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 20 quarters.
  • Parallax Volatility Advisers's Sarepta Therapeutics position peaked at $4.45M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.